Bretton Fund Exited Revvity (RVTY) in 2025

Key Takeaways

• Bretton Fund posted 11.58% annual return vs 17.88% S&P
• Revvity fell 13% over 52 weeks, market cap $11.2B
• Fund criticized Revvity's post‑COVID acquisitions and divestitures
• Hedge fund ownership of Revvity rose to 35 portfolios
• Fund favors AI stocks with higher upside, lower risk

Summary

Bretton Capital Management’s Bretton Fund posted an 11.58% return for 2025, lagging the S&P 500’s 17.88% gain. In its Q4 2025 investor letter the fund disclosed a complete exit from Revvity (RVTY), citing disappointing post‑COVID acquisitions and a slowdown in pharma research spending. The fund described the broader AI‑driven market as “modestly elevated” but not a bubble, and it is trimming speculative AI exposure in favor of longer‑term value. Revvity’s shares closed at $98.49, down 13% over the past year, with a market cap of $11.2 billion.

Pulse Analysis

Bretton Capital Management’s latest quarterly letter underscores a cautious stance on the AI‑driven market rally. While the fund still acknowledges a "golden age" for medicine, it flags that the sector’s excitement may be overstated, prompting a reduction of speculative positions. By exiting Revvity, the fund illustrates how even companies with strong health‑science platforms can suffer when management misallocates capital, as seen with costly acquisitions and the divestiture of a cash‑generating food‑testing unit. This move aligns the fund’s performance metrics—11.58% annual return versus the S&P’s 17.88%—with a longer‑term risk‑adjusted outlook.

Revvity’s recent trajectory offers a cautionary tale for investors chasing AI‑adjacent growth. The company’s stock slipped 13% over the past 52 weeks, and its market capitalization sits at roughly $11.2 billion, reflecting waning confidence after a pandemic‑era windfall was spent on overpriced deals. Hedge fund exposure rose modestly to 35 portfolios, indicating lingering interest despite the setbacks. Analysts point to a broader slowdown in pharma research budgets and tighter FDA spending, which erodes demand for Revvity’s consumables. The fund’s criticism highlights the importance of disciplined capital allocation in a sector where hype can quickly outpace fundamentals.

The broader implication for the investment community is a pivot toward AI stocks that combine robust cash flows with clearer pathways to profitability. Bretton’s decision to favor AI opportunities with higher upside and lower downside risk suggests a re‑calibration of risk appetite across hedge funds. Investors should scrutinize the balance between speculative growth and sustainable earnings, especially in biotech and health‑science firms where regulatory and research cycles can dramatically shift market dynamics. By emphasizing long‑term value over short‑term hype, funds like Bretton aim to protect returns while still participating in the transformative potential of AI in medicine.